Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials
作者： Marc Buyse
DOI: 10.1097/PPO.0B013E3181B9C602
关键词:
摘要: This article discusses statistical approaches to the validation of surrogate biomarkers and endpoints. One approach that has been successfully used in oncology consists estimating associations at two levels: association between clinical endpoint, called individual-level association, effects treatment on trial-level association. requires data be available from multiple randomized trials, such as a meta-analysis trials based individual patient data. The is illustrated using first-line treatments for advanced tumors colon, breast, ovary, prostate. Data several meta-analyses suggest progression-free survival an acceptable colorectal ovarian cancer, but not breast prostate cancer.
lww.com
sci-hub.se 参考文章(42)
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
D C Smith, R L Dunn, M S Strawderman, K J Pienta, Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. Journal of Clinical Oncology. ,vol. 16, pp. 1835- 1843 ,(1998) , 10.1200/JCO.1998.16.5.1835
Marissa N Lassere, Robert Landewe, Clifton O Bingham, Philip Mease, Vibeke Strand, Peter Tugwell, Kent R Johnson, Kent R Johnson, Lee Simon, Richard Wakefield, Walter P Maksymowych, Michael Hughes, Mikkel Ostergaard, Paul-Peter Tak, Peter Brooks, Barry Bresnihan, Maarten Boers, Marc Buyse, Sally Galbraith, Doug Altman, George Wells, Philip G Conaghan, Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. The Journal of Rheumatology. ,vol. 34, pp. 607- 615 ,(2007)
Ariel Alonso, Geert Molenberghs, Surrogate marker evaluation from an information theory perspective. Biometrics. ,vol. 63, pp. 180- 186 ,(2007) , 10.1111/J.1541-0420.2006.00634.X
Marc Buyse, Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer International Journal of Clinical Oncology. ,vol. 14, pp. 95- 101 ,(2009) , 10.1007/S10147-009-0879-2
Marc Buyse, Geert Molenberghs, Criteria for the validation of surrogate endpoints in randomized experiments Biometrics. ,vol. 54, pp. 1014- 1029 ,(1998) , 10.2307/2533853
Tomasz Burzykowski, Marc Buyse, Greg Yothers, Junichi Sakamoto, Dan Sargent, Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Analysis. ,vol. 14, pp. 54- 64 ,(2008) , 10.1007/S10985-007-9079-4
Ariel Alonso, Geert Molenberghs, Helena Geys, Marc Buyse, Tony Vangeneugden, A unifying approach for surrogate marker validation based on Prentice's criteria Statistics in Medicine. ,vol. 25, pp. 205- 221 ,(2006) , 10.1002/SIM.2315
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Tomasz Burzykowski, Marc Buyse, Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharmaceutical Statistics. ,vol. 5, pp. 173- 186 ,(2006) , 10.1002/PST.207